(Adnkronos) - I pazienti affetti da mieloma multiplo e da neoplasia a cellule dendritiche plasmacitoidi blastiche hanno oggi a disposizione nuove prospettive terapeutiche. Si tratta di selinexor, inibitore orale selettivo della proteina XPO1, approvato alla rimborsabilità da Aifa in associazione a bortezomib e desametasone per il trattamento di pazienti adulti con mieloma multiplo sottoposti ad almeno una terapia precedente; e di tagraxofusp, prima terapia specifica per la neoplasia a cellule dendritiche plasmacitoidi blastiche approvata alla rimborsabilità nel marzo 2023 e i cui risultati di efficacia in real life superano quelli degli studi clinici.
Category
🗞
NewsTranscript
00:00The Italian Pharmaceutical Agency has approved the reimbursement of Selinexor for the treatment
00:09of adult patients with multiple myeloma undergone at least one previous therapy.
00:14The selective oral inhibitor of the protein XPO1 is therefore now reimbursable in two
00:19indications.
00:20The first is for the use of Selinexor in association with desamethasone, which is a cortisone,
00:32as a fifth-line therapy in patients who have previously been exposed to two protein inhibitors,
00:44the monomodulants, and an anti-CD38 monoclonal antibody.
00:51The other indication, on the other hand, is in association with a protein inhibitor called
00:58Bortezomib.
00:59Selinexor and Bortezomib, in association with desamethasone, have received the approval
01:08on the basis of the results of a Phase III study, the Boston study.
01:13The new therapeutic option, being orally administered, also contributes to improving
01:19the quality of life of the patient.
01:21A therapy that therefore allows the person not to have to be in the hospital to be able
01:26to receive it in the administration, and therefore this also frees the caregiver from the need
01:32to accompany the person in the hospital.
01:34An important event in the oncological field is also that of Tagraxofusp, the first specific
01:40for neoplasia, with dendritic and plasmocytoid blasts, whose effectiveness has been evidenced
01:46by a study conducted on 47 patients, 32 of whom had not previously been treated.
01:52The results have been extremely comforting because the untreated patients have had a
02:00complete response of 72%, putting together complete and partial responses, therefore
02:08in what we call overall response rate, we are talking about numbers of 90%.
02:14As for the patients who had already seen previous treatments, 67% got an answer.
02:23Results that are a source of pride for Menarini, which for a few years has chosen to engage
02:28in the research and development of new therapeutic solutions for blood tumors.
02:33As the Menarini Group, we are proud to have embarked a few years ago on this path of commitment
02:39in the research and development of drugs in the oncological field, and the next steps
02:44will certainly go in this direction, trying to bring as much innovation as possible
02:50for patients affected by blood tumors.